ProjektEMPA-KIDNEY® Kids – A randomised, double-blind, placebo-controlled trial with anopen-label extension to assess the…

Grunddaten

Akronym:

EMPA-KIDNEY® Kids

Titel:

A randomised, double-blind, placebo-controlled trial with anopen-label extension to assess the pharmacokinetics, safety,and efficacy of empagliflozin tablets in paediatric patientswith chronic kidney disease

Laufzeit:

01.12.2025 bis 31.12.2029

Abstract / Kurz- beschreibung:

The aim of this trial: Provide assessments of PK, safety, and efficacy of empagliflozin in a
broad patient population with proteinuric CKD, aged 2 to 17 years, regardless of etiology.

Schlüsselwörter:

chronic kidney disease

SGLT2 inhibitor

proteinuria